Zacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Post Quarterly Sales of $44.00 Million
Brokerages forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post $44.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Vanda Pharmaceuticals’ earnings. Vanda Pharmaceuticals posted sales of $38.24 million during the same quarter last year, which suggests a positive year over year growth rate of 15.1%. The company is expected to report its next earnings report on Wednesday, February 21st.
On average, analysts expect that Vanda Pharmaceuticals will report full-year sales of $44.00 million for the current financial year, with estimates ranging from $164.80 million to $165.70 million. For the next fiscal year, analysts expect that the firm will report sales of $0.00 per share. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $41.30 million for the quarter, compared to the consensus estimate of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business posted ($0.01) EPS.
VNDA has been the topic of a number of research reports. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Piper Jaffray Companies set a $26.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 19th. ValuEngine downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Finally, Oppenheimer set a $26.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $21.50.
Vanda Pharmaceuticals (NASDAQ:VNDA) traded down $0.30 during trading on Tuesday, hitting $14.20. The stock had a trading volume of 602,372 shares, compared to its average volume of 589,690. The stock has a market cap of $642.46, a P/E ratio of -44.38 and a beta of 1.29. Vanda Pharmaceuticals has a 52 week low of $11.90 and a 52 week high of $18.99.
In related news, CFO James Patrick Kelly sold 9,155 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total transaction of $140,529.25. Following the sale, the chief financial officer now directly owns 144,721 shares in the company, valued at approximately $2,221,467.35. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Gunther Birznieks sold 8,568 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total value of $130,747.68. Following the sale, the senior vice president now owns 118,366 shares in the company, valued at $1,806,265.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 209,483 shares of company stock worth $3,205,205. Company insiders own 7.60% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. California Public Employees Retirement System raised its holdings in shares of Vanda Pharmaceuticals by 3.8% during the 2nd quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock valued at $971,000 after buying an additional 2,200 shares during the period. Legal & General Group Plc raised its holdings in shares of Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Vanda Pharmaceuticals by 1.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 199,578 shares of the biopharmaceutical company’s stock valued at $3,573,000 after buying an additional 3,305 shares during the period. Voya Investment Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 29.7% during the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 4,605 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Vanda Pharmaceuticals by 1.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 318,788 shares of the biopharmaceutical company’s stock valued at $5,196,000 after buying an additional 4,986 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/zacks-brokerages-anticipate-vanda-pharmaceuticals-inc-vnda-will-post-quarterly-sales-of-44-00-million/1809849.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.